- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Interventions
- BGB-A445, tislelizumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Interventions
- IDE196, Binimetinib, Crizotinib
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
- Conditions
- Prostate Cancer
- Interventions
- Relugolix, Leuprorelin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
- Conditions
- Genetic Predisposition to Disease, Genetic Predisposition
- Interventions
- Nest Platform
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Opioid Use Disorder
- Interventions
- Methadone, Patient Navigation, Enhanced Treatment as Usual (ETAU)
- Drug · Behavioral
- Lead sponsor
- Friends Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Heart Failure
- Interventions
- BiDil XR, BiDil Immediate Release (IR)
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Coral Gables, Florida • Jacksonville, Florida + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 404
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Denver, Colorado • Louisville, Kentucky + 2 more
- Conditions
- Advanced Angiosarcoma
- Interventions
- TRC105, Votrient
- Biological · Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Palo Alto, California • Santa Monica, California + 22 more
- Conditions
- Heart Failure, Central Sleep Apnea
- Interventions
- Oxygen, Room Air
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Stanford, California • New Haven, Connecticut + 20 more
- Conditions
- Genital Neoplasm, Female
- Interventions
- Discharge instructions reminders, Prompts to report symptoms via the web-enabled app, Clinical Alerts
- Behavioral
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Southaven, Mississippi • Memphis, Tennessee
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, Etoposide, Pembrolizumab, Radiation
- Drug
- Lead sponsor
- Nathan Pennell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Dizziness, Vertigo
- Interventions
- Pentoxifylline, Placebo
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- PolG, Primary Mitochondrial Myopathy
- Interventions
- Not listed
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Kingston, Massachusetts
- Conditions
- Smith-Lemli-Opitz Syndrome
- Interventions
- Cholesterol Suspension, CRH, Cholesterol
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Von Hippel Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
- Interventions
- PC2: Primary Care Connect
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Advanced Solid Tumors, Lymphoma
- Interventions
- epacadostat, SD-101, Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Bacterial Infections, Wounds
- Interventions
- Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin
- Drug
- Lead sponsor
- Robert S Berman MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Jupiter, Florida